[15] 日本うつ病学会 [Internet]. 日本うつ病学会治療ガイドライン II. うつ病（DSM－5）／大うつ病性障害 2016 [cited 2018 Jul 19]. Available from: http://www.secretariat.ne.jp/jsmd/mood_disorder/img/160731.pdf

[16] 樋口輝彦．うつ病－維持療法－．臨床精神医学．2006;35（増刊号）:85-92.

[17] Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH, et al [Internet]. Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition [cited 2018 Jul 20]. American Psychiatric Association. 2010. Available from: https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf

[18] Lam RW, Kennedy SH, Grigoriadis S, McIntyre RS, Milev R, Ramasubbu R, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. Journal of Affective Disorders. 2009;117:S26-S43.

[19] 日本うつ病学会[Internet]. SSRI/SNRI を中心とした抗うつ薬適正使用に関する提言 [cited 2018 Jul 19]. Available from: http://www.secretariat.ne.jp/jsmd/koutsu/pdf/antidepressant%20.pdf

[20] 上田展久、中村　純．抗うつ薬の副作用と対策．日本臨牀．2001;59(8):1535-1538.

[21] Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.

[22] Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289(23):3095-3105.

[23] Greer TL, Kurian BT, Trivedi MH. Defining and measuring functional recovery from depression. CNS Drugs. 2010;24(4):267-284.

[24] Jaeger J, Berns S, Uzelac S, Davis-Conway S. Neurocognitive deficits and disability in major depressive disorder. Psychiatry Research. 2006;145:39-48.

[25] Baune BT, Renger L. Pharmacological and non-pharmacological interventions to improve cognitive dysfunction and functional ability in clinical depression - A systematic review. Psychiatry Research. 2014;219:25-50.

[26] McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. International Journal of Neuropsychopharmacology. 2016;19(10):.

[27] Kikuchi T, Uchida H, Suzuki T, Watanabe K, Kashima H. Patients' attitudes toward side effects of antidepressants: an Internet survey. Eur Arch Psychiatry Clin Neurosci. 2011;261:103-109.

[28] Culpepper L, Davidson JRT, Dietrich AJ, Goodman WK, Kroenke K, Schwenk TL. Suicidality as a Possible Side Effect of Antidepressant Treatment. Prim Care Companion J Clin Psychiatry. 2004;6(2):79-86.

[29] Nierenberg AA, Husain MM, Trivedi MH, Fava M, Warden D, Wisniewski SR, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med. 2010;40(1):41-50.

[30] Yang H, Sinicropi-Yao L, Chuzi S, Youn SJ, Clain A, Baer L, et al. Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine. Annals of General Psychiatry. 2010;9:10.

[31] Nierenberg AA, Adler LA, Peselow E, Zornberg G, Rosenthal M. Trazodone for antidepressant-associated insomnia. Am J Psychiatry. 1994;151(7):1069-1072.

[32] Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry. 2010;71(10):1259-1272.

[33] 伊賀淳一．うつ病維持療法ガイドライン．臨床精神薬理．2017;20(5):505-512.

[34] Baldessarini RJ, Tondo L, Ghiani C, Lepri B. Illness risk following rapid versus gradual discontinuation of antidepressants. Am J Psychiatry. 2010;167(8):934-941.

[35] 渡部芳徳、渡邊衡一郎、平野陽子、浅見優子．近年の抗うつ薬の国内臨床試験におけるプラセボ反応性．臨床精神薬理．2017;20(5):565-579.

[36] Pehrson AL, Sanchez C. Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectrums. 2014;19:121-133.

[37] Mørk A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, et al. Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacology, Biochemistry and Behavior. 2013;105:41-50.

[38] Pehrson AL, Cremers T, Bétry C, van der Hart MGC, Jørgensen L, Madsen M, et al. Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters-A rat microdialysis and electrophysiology study. European Neuropsychopharmacology. 2013;23:133-145.

[39] Garnock-Jones KP. Vortioxetine: a review of its use in major depressive disorder. CNS Drugs. 2014;28(9):855-74.

[40] Nutt DJ. Beyond psychoanaleptics - can we improve antidepressant drug nomenclature? J Psychopharmacol 2009;23(4):343-5.

[41] Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011;54(9):3206-21.

[42] Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics. 2015;145:43-57.

[43] Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015 Apr;20(2):93-7.

[44] Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectr. 2015 Oct;20(5):455-9.

[45] Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr. 2015 Dec;20(6):515-9.

[46] Areberg J, Luntang-Jensen M, Søgaard B, Nilausen DØ. Occupancy of the serotonin transporter after administration of Lu AA21004 and its relation to plasma concentration in healthy subjects. Basic & Clinical Pharmacology & Toxicology. 2012;110:401-404.

[47] Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin Transporter Occupancy of Five Selective Serotonin Reuptake Inhibitors at Different Doses: An [^{11}C]DASB Positron Emission Tomography Study. Am J Psychiatry. 2004;161:826-835.

[48] Guilloux JP, Mendez-David I, Pehrson A, Guiard BP, Repérant C, Orvoën S, et al. Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology. 2013;73:147-159.

[49] Zhang ZJ, Schmidt DE, de Paulis T, Trivedi BL, Onaivi ES, Ebert MH, et al. Anxiolytic-like effects of DAIZAC, a selective high-affinity 5-HT$_3$ receptor antagonist, in the mouse elevated plus-maze. Pharmacology, Biochemistry and Behavior. 2001;69:571-578.

[50] Meneses A. 5-HT system and cognition. Neuroscience and Biobehavioral Reviews. 1999;23:1111-1125.

[51] Haddjeri N, Etiévant A, Pehrson A, Sánchez C, Bétry C. Effects of the multimodal antidepressant Lu AA21004 on rat synaptic and cellular hippocampal plasticity and memory recognition. Eur Neuropsychopharmacol. 2012;22:S303.

[52] Wallace A, Pehrson AL, Sánchez C, Morilak DA. Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. International Journal of Neuropsychopharmacology. 2014;17:1695-1706.

[53] Siddiqui A, Niazi A, Shaharyar S, Wilson CA. The 5HT$_7$ receptor subtype is involved in the regulation of female sexual behaviour in the rat. Pharmacology, Biochemistry and Behavior. 2007;87:386-392.

[54] Ahlenius S, Larsson K. Evidence for an involvement of 5-HT$_{1B}$ receptors in the inhibition of male rat ejaculatory behavior produced by 5-HTP. Psychopharmacology. 1998;137:374-382.

[55] Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77-87.

[56] Bostwick JM. A generalist's guide to treating patients with depression with an emphasis on using side effects to tailor antidepressant therapy. Mayo Clin Proc. 2010;85(6):538-550.

[57] Passani MB, Blandina P, Torrealba F. The histamine H$_3$ receptor and eating behavior. J Pharmacol Exp Ther. 2011;336(1):24-29.

[58] Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, et al. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol. 2016;30(3):242-252.

[59] 白川　治．静穏作用を示す抗うつ薬 mirtazapine の位置づけ．臨床精神薬理．2011;14(1):181-187.

[60] Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, et al. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology. 2017;27:773-781.

[61] Garcia-Toro M, Medina E, Galan JL, Gonzalez MA, Maurino J. Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment. BMC Psychiatry. 2012;12:143.

[62] McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. International Journal of Neuropsychopharmacology. 2014;17:1557-1567.

[63] Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology. 2015;40:2025-2037.

[64] Thase ME, Mahableshwarkar AR, Dragheim M, Loft H, Vieta E. A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. European Neuropsychopharmacology. 2016;26:979-993.

[65] Baldwin DS, Florea I, Jacobsen PL, Zhong W, Nomikos GG. A meta-analysis of the efficacy of vortioxetine in patients with major depressive disorder (MDD) and high levels of anxiety symptoms. Journal of Affective Disorders. 2016;206:140-150.

[66] Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. International Clinical Psychopharmacology. 2012;27(4):215-223.

[67] Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med. 2015;12:2036-2048.

[68] Jacobsen PL, Mahableshwarkar AR, Palo WA, Chen Y, Dragheim M, Clayton AH. Treatment-emergent sexual dysfunction in randomized trials of vortioxetine for major depressive disorder or generalized anxiety disorder: a pooled analysis. CNS Spectrums. 2016;21:367-378.

[69] Bialik RJ, Ravindran AV, Bakish D, Lapierre YD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci. 1995;20(4):265-270.

2.5.7.2 「2.5.2 生物薬剤学に関する概括評価」で使用した参考文献

該当なし。

2.5.7.3 「2.5.3 臨床薬理に関する概括評価」で使用した参考文献

[1] Meyer JH, Wilson AA, Sagrati S, Hussey D, Carella A, Potter WZ, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [^{11}C]DASB positron emission tomography study. Am J Psychiatry 2004;161(5):826-35.

2.5.7.4 「2.5.4 有効性の概括評価」で使用した参考文献

[1] 抗うつ薬の臨床評価方法に関するガイドライン(平成 22 年 11 月 16 日付薬食審査発 1116 第 1 号)

[2] Olfson M, Fireman B, Weissman MM, Leon AC, Sheehan DV, Kathol RG, et al. Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry. 1997;154(12):1734-40.

[3] Bialik RJ, Ravindran AV, Bakish D, Lapierre YD. A comparison of placebo responders and nonresponders in subgroups of depressive disorder. J Psychiatry Neurosci. 1995;20(4):265-70.

[4] Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7), 723-33.

[5] Montgomery SA, Möller HJ.Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? .Int Clin Psychopharmacol. 2009;24(3):111-8

[6] 日本うつ病学会 [Internet]. 日本うつ病学会治療ガイドライン II.うつ病（DSM－5）／大うつ病性障害 [cited 2018 Jul 19]. Available from: http://www.secretariat.ne.jp/jsmd/mood_disorder/img/160731.pdf

2.5.7.5 「2.5.5 安全性の概括評価」で使用した参考文献

[1] Montgomery SA. Antidepressants and seizures: emphasis on newer agents and clinical implications. Int J Clin Pract. 2005;59:1435-40.

[2] Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112-20.

[3] Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports. CMAJ. 1996;155(5):519-27.

[4] Wallerstedt SM, Gleerup H, Sundström A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients--influence of SSRI treatment. Pharmacoepidemiol Drug Saf. 2009;18:412-6.

[5] Dalton SO, Johansen C, Mellemkjaer L, Nørgård B, Sørensen HT, Olsen JH. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163: 59-64.

[6] Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; on behalf of the Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. World J Biol Psychiatry. 2013;14:334-85.

[7] 高塩　理．性機能障害．臨床精神医学．2014;43(11):1617-24.

[8] 日本うつ病学会 [Internet]. SSRI/SNRI を中心とした抗うつ薬適正使用に関する提言. [cited 2018 Jul 19]. Available from: http://www.secretariat.ne.jp/jsmd/koutsu/pdf/antidepressant%20.pdf

2.5.7.6 「2.5.6 ベネフィットとリスクに関する結論」で使用した参考文献

[1] 髙橋三郎、大野　裕（監訳）. DSM-5 精神疾患の診断・統計マニュアル. 医学書院. 2014.

[2] 日本うつ病学会 [Internet]. 日本うつ病学会治療ガイドライン II. うつ病（DSM－5）／大うつ病性障害 2016 [cited 2018 Jul 19]. Available from: http://www.secretariat.ne.jp/jsmd/mood_disorder/img/160731.pdf.

[3] Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D Report. Am J Psychiatry. 2008;165(3):342-51.

[4] Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D Report. Am J Psychiatry. 2006;163(11):1905-17.

[5] Montgomery SA, Möller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009;24(3):111-8.

[6] 樋口輝彦. うつ病－維持療法－. 臨床精神医学. 2006;35（増刊号）:85-92.

[7] Hill T, Coupland C, Morriss R, Arthur A, Moore M, Hippisley-Cox J. Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64 years: cohort study using a primary care database. BMC Psychiatry. 2015;15:315.

[8] Degner D, Grohmann R, Kropp S, Rüther E, Bender S, Engel RR, et al. Severe adverse drug reactions of antidepressants: Results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry. 2004;37(Suppl 1):S39-45.

[9] Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008;52(1):144-53.

[10] Stone M, Laughren T, Jones ML, Levenson M, Holland PC, Hughes A, et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ. 2009;339:b2880.

[11] de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: Mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging. 2011;28(5):345-67.

[12] Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf. 2008;17(8):801-6.

[13] Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med. 2006;354(6):579-87.